Get startedLog in
    Picture of Odi Pharma AB (publ) logo

    ODI — Odi Pharma AB (publ) Income Statement

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Odi Pharma AB (publ), fiscal year end - June 30th, SEK millions except per share, conversion factor applied.

    2022
    June 30th
    2023
    June 30th
    2024
    June 30th
    2025
    June 30th
    2026
    June 30th
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSPRESS
    Standards:
    SAS
    SAS
    SAS
    SAS
    SAS
    Status:FinalFinalFinalFinalPreliminary
    Revenue
    Total Revenue0.3130.13922.33.1332.9
    Cost of Revenue
    Gross Profit-5.6-5.69-0.295-3.886.33
    Selling / General / Administrative Expenses
    Depreciation and Amortization
    Other Operating Expenses
    Total Operating Expenses7.526.9521.98.5930.4
    Operating Profit-7.21-6.810.428-5.452.5
    Total Net Non Operating Interest Income / Expense
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-7.24-6.9-0.379-5.931.99
    Provision for Income Taxes
    Net Income After Taxes-7.24-6.9-0.568-5.931.99
    Net Income Before Extraordinary Items
    Net Income-7.24-6.9-0.568-5.931.99
    Adjustments to Net Income
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Dilution Adjustment
    Diluted Net Income-7.24-6.9-0.568-5.931.99
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-0.475-0.453-0.037-0.3240.11
    Dividends per Share